ArticleFrontiers in cardiovascular medicine2025
Global, regional, and national burden of non-rheumatic valvular heart disease and Its projections to 2035: comprehensive analysis of the global burden of disease study 2019.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Temporal trends of atrial fibrillation and atrial flutter burden across the BRICS: An observational study analysis for the GBD 2021.Medicine · 2026Observational
- Changing trends in burden of calcific aortic valve diseases and degenerative mitral valve diseases among people aged 60-89 years from 1990 to 2030.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Valvular heart disease has attracted global attention as the next heart epidemic. However, the control effect of non-rheumatic valvular heart disease (NRVHD) is not ideal. We systematically and comprehensively assessed the epidemiological information and attributable risk factors of NRVHD from 1990 to 2019, and projections by 2035. Methods: Data on NRVHD were from the Global Burden of Disease (GBD) 2019. We analyzed the disease burden by age, sex, and socio-demographic index (SDI) regions from 1990 to 2019 using the Joinpoint regression model. We calculated attributable mortality and disability-adjusted life years (DALYs) associated with potential risk factors using a comparative risk assessment. Additionally, Nordpred age-period-cohort analysis predicted the NRVHD burden for the next 15 years. Results: From 1990 to 2019, incident, prevalent, and death cases, and DALYs of NRVHD gradually increased globally. The age-standardized incidence (ASIR) and prevalence rate (ASPR) of NRVHD continued to increase, while age-standardized mortality (ASMR) and DALYs rate (ASDR) gradually decreased. Subgroup analysis stratified by age, sex, and SDI regions suggested: (1) The global burden of NRVHD in women is generally decreasing. (2) In people older than 55 years, ASPR and ASIR continued to increase with aging, but the decline of ASMR and ASDR was relatively flat. (3) Despite an overall decline in ASMR and ASDR, the disease burden of NRVHD was highest in high SDI regions. High systolic blood pressure was the most prominent risk factor for NRVHD, with much higher mortality and DALYs than the high-sodium diet and lead exposure. The Nordpred age-period-cohort analysis demonstrated that ASIR (20.28 per 100,000 population) is on an upward trend, and ASMR (2.06 per 100,000 population) and ASDR (33.74 per 100,000 population) are on a downward trend in the next 15 years. Conclusion: The global burden of NRVHD remains high, especially among older adults and men in high SDI areas. However, ASMR and ASDR have declined for nearly 10 years and will likely continue to do so for the next 15 years. This suggests that current medical interventions and hypertension control strategies have been effective in reducing the NRVHD burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.